This is the link to PFE's experimental breast cancer drug:
There has been considerable discussion lately in the news articles that PFE might be getting ready to unload its profitable generic business and focus more on expanding its branded drug portfolio. Last year PFE's generic business generated about $7 billion in revenue. Do you think selling this business would be an appropriate measure to take at this time.
Why were you right on target with PFE. You unloaded PFE in the high 20's and since then it has been over 32. This year it may even go higher
I sold my PFE shares yesterday at 29.5. The stock price was even a little higher today, max of 29.9. Long term, I still believe that PFE will do well. The CEO Ian Read is really trying his best to return value to the shareholders and in due time I think his efforts will pay off. I sold my shares because I am retired now and in my stage of life (over 70) I thought it was risky to keep a significant portion of my retirement portfolio in a single stock. If i were younger and still working I wouldn't hesitate to continue to invest in PFE. It's a great company and a great stock. Good luck to all of you!
The positive factor regarding Q2 earnings is the recent $10 billion stock buy-back which should boost EPS. The biggest concern is the sales revenue. Weak foreign currencies in countries where PFE does business and aggressive competition from the generic companies were the two primary reasons cited for missing the Q1 revenue target. Unfortunately those two issues still exist. I have also read some reports that the revenue obtained this year from the new BMY/PFE blood thinner drug, Eliquis, is lower than expected. Hopefully the Q2 sales revenue will not disappoint.
I think all serious PFE investors are anxious for the stock price to turn around and go up again. MRK and BMY are currently seeing the same softness in their stock's performance so it seems to be a sector issue. I personally believe that Ian Read is doing a reasonably god job as the PFE CEO in bringing value to the shareholders. Let's not forget and be appreciative of the run- up of the PFE stock from 19 to a high over 30 in April of this year in roughly a two year period. Read and his staff still are contending will the huge revenue hole that was left when Lipitor expired to the tune of $13B per year. That amount of revenue is not at all easy to replace. However PFE has some exciting drugs in its pipeline including a very promising cancer drug that achieved FDA breakthrough status not long ago. Although momentarily it seems to have fallen out of favor, PFE is still a strong company with solid fundamentals and as such I believe the stock price will eventually start going up again.
with investors. Lately it has been going down, down, down. The announcement of a $10 billion stock buyback didn't seem to have any effect. The stock has been downgraded by one analyst to 24. What else is left? An acquisition?
Over the last few weeks PFE has been mired in a very narrow trading range centered around 28. Lately its performance has been very predictable. If it goes up at the starting bell it generally loses its again in the afternoon and often ends up in the red at the closing been. Even the recent announcement of the $10 billion stock buy-back hasn't improved the momentum. This may be an ominous sign before the second quarter earnings report next month. The stock price hasn't yet recovered when it tanked after the dismal first quarter report numbers. None of us would like that repeated. The stock price was just a little over 31 on April 19. Do you think it will climb back to 30 this year?
looks tired and acts as if it is fully valued at 28. Perhaps it is. PFE many times increases during the morrning, gives up its gain in the afternoon, and goes in the red before the closing bell. Other pharmas such as BMY, MRK, LLY, and JNJ more times than not hold onto thier gains during the day. Today is a typical case when the market is up by triple digits and PFE is barely hanging on. This pattern is frustrating.
Why did PFE end up in the red today when other big pharmas such as MRK, BMY, JNJ, and LLY posted solid gains? I've noticed lately that PFE starts up well but languishes as the day goes by. It needs a strong dose of Viagra.
When I first tried to post my messages on the PFE message board, I wanted to use the name gallantfox. I have always been a huge horse racing fan evey ssince I was a little kid and I really liked the names of many of the horses, particularly Gallant Fox. I tried to sign in as gallantfox but I couldn't because the name had alreadly been taken by someone else. I played with variations of this name and discovered that I could use galantfoxjr as a legitimate new name.
You need to seriously think about what you plan to post before you do it. It could save you a lot of embarassment You come across as a stark raving moron.
You my friend are an absolute moron. I didn't have the foggiest idea what you were referriing to in your post. I am a serious PFE investor who tries to share important PFE related issues with normal people on this board which leaves you out. completely. I have no hidden agenda, plain and simple. Go stuff it.
I am certainly a novice in the oncology area but what I have read so far, the early stage results wiith the immune system cancer drugs have been exciting. Merck 's immune system drug to treat advanced melanoma has shown very good results in early trials as has a combo set of drugs from BMY based on the same principle. The analysts that attended last week-end's cancer conference where the latest immune system results were reported were certainly impressed. We are all skeptical of 'Holy Grail' miraclle drugs for serious diseases which certainly includes me but this particular approach may have profound consequences. If the blocks that normally prevent the body's immune system to recognize and selectively kill cancer cells can be removed then theoretically it should be possible to cure at least certain types of deadly cancers without having to resort to using archaic, non-specific, chemotheorapy and radiation treatments which have horrible side effects. In my opinion, Pfizer indeed needs to seriously investigate thie immune sytem approach for treating cancer, regardless of how involved it is in other cancer treatments because there is the possiblity that this approach may turn out to be head and shoulders better than all of the others.
A number of big pharmas such as Roche, BMY, and Merck are hard at work trying to develop a new type of cancer drug that disables certain proteins in the body such as PD-1 that prevent the immune system from recognizing and destroying cancer cells. There was a big medical conference that was held this past week -end that was specifically dedicated to this exciting new area of cancer research. Quess what? PFE wasn't represented in the conference because it isn't even involved yet in this arena which it cetainly needs to do before it is too late.
Thanks for your reply. I posted another message this morning entitled "Why PFE had a bad week' which was just an excerpt from a current PFE news artice. This article did indeed confirm your arguments that during last week there was a broad base decline of dividend paying stocks triggered by the concern that the FED may increase the interest rate which will put Treasury bonds in competition with the dividend stocks such as PFE. The article that I posted also mentioned that an analyst from Suntrust gave PFE a target price of 27 which might have been another reason for the decline in the PFE stock price last week. An increase in interest rates whould indeed be expected to; have and adverse affect on defensive, dividend stocks such as PFE and hence that possibility is a legitimate
concern that particularly bothers me.
Pfizer (NYSE: PFE ) lost 6.23% this past week, with the largest one-day decline coming on Friday after the stock was hit with a trifecta of problems. First, the health-care industry had a rough day, in general, led by UnitedHealth, which lost 3.14% during the regular trading session during the day. Second, the stock was given a 12-month price target of $27 per share by an analyst at SunTrust. And lastly, rising interest rates is having a negative effect on stable high yielding blue-chip stocks, as investors leave riskier equities in favor of risk-free Treasury bonds, which are currently paying nearly identical yields as the Pfizer's 3.3% dividend. Thinterest-rate pressure was a running theme within the Dow this week, as all three of the top losers likely experienced investors bailing on stable stocks in favor of the "safety" of bonds.
P.S. I copied this from a PFE news item that appeared today. Makes sense.
You really didn't answer my two essentially yes or no questions. Do you sitll have the same optimistic opinion of PFE after it tanked about 5% over the last five days (yes or no) and was the sudden drop a big surprise to you (yes or no)? We all know that last week wasn't really a good one for any of the big pharmas. My concern as a big PFE investor is that it was indeed worst for PFE compared to its peer such as BMY, MRK, and LLY. Over the last five days BMY and MRK showed 0% net change.. Lilly lost 2% but PFE lost 5%, the undisputed heaviest loser. Let us be very clear about this. I think we are both in the same camp as far as what we would like to see happen with PFE stock so I am certainly not trying to pick on you. To the contrary, I have been reasonably impressed with your posts. I was simply asking what your reaction was to the 5% drop in the PFE stock price over such a short period of time #$%$ days.